The objective of this study was to estimate whether the risk of death from COVID-19 in patients with multiple sclerosis (MS) exceeds that of the general population.

In this article the authors reviewed all vaccine related CVT published cases by April 30, 2021.

This study aims to determine the profile and possible mechanisms behind CNS inflammatory diseases in the context of COVID-19.

This bi-center longitudinal study evaluated symptoms in consecutive COVID-19 patients in the participating practices.

In this article the authors provide an overview on BTKi mechanisms relevant to COVID-19 infection and vaccination and review preliminary data on BTKi use in patients with COVID-19.

This Self-controlled case series study using national data on COVID-19 vaccination and hospital admissions.

In this study the authors investigated the effect of vaccination of health care workers in Scotland on the risk of coronavirus disease 2019 (COVID-19) among members of their households.

In this ongoing trial, the authors randomly assigned 44,165 participants aged 16 or older and 2,264 participants aged 12-15 to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo.

EAN was able to welcome 46 participants from 15 countries - Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Portugal, Romania, Russia, Spain, Tunisia, Turkey and Ukraine - to Loutraki.

The objective of this study was to explore the perceived impact of confinement in patients with Parkinson's disease and document the effects of gender and living environment.

This study aimed to explore the associations of objective cognitive performances and psychological distress with cognitive complaints in COVID-19 survivors.

The objective of this study was to determine clinical characteristics and outcomes in hospitalised PD individuals infected with COVID-19.

The objective of this study was to determine whether previously identified risk factors for 30-day mortality in Dutch NH residents with COVID-19 are unique to COVID-19.

In this review, the authors summarize possible mechanisms by which infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, may cause AD in elderly COVID-19 patients and describe preventive measures to mitigate risk.

The European Federation of Neurological Associations, in partnership with the NeuroCOVID-19 taskforce of the European Academy of Neurology, has investigated the impact of the first wave of the COVID-19 pandemic on patients with neurological diseases, as well as the hopes and fears of these patients about the post-pandemic phase.